Jaguar Health’s Napo Pharma Satisfies Conditions Required To Receive Payment Of Non-Dilutive $2M Holdback Amount From Future Pak Related To US Commercial Licensing Agreement
As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized
Jaguar Health is getting an extra $2 million from a partner company because they hit certain goals with their medicines in the U.S. When a company earns money from deals like this instead of selling new stock, it shows their products are working well enough that partners want to pay them.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.